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Branch retinal vein occlusion (BRVO) is a common
cause of retinal vascular disease [1]. It affects males and
females equally. This disease occurs most frequently
between 60 and 70 years of age, and most commonly
occurs at arteriovenous crossings, where the artery
and vein share a common adventitial sheath [2–4].
Patients often complain of sudden onset of blurred
vision or visual field defect. Fundus reveals intraretinal
hemorrhage, retinal edema and, often, cotton-wool
spots in a sector of retina drained by the affected
vein. The most common site is at the superotemporal
quadrant [5–8]. The vision-limiting complications
include macular edema, macular nonperfusion, and
vitreous hemorrhage from neovascularization [9–12].
The degree of macular involvement determines the
level of visual impairment. Previous treatment for
this condition included anticoagulant therapy [13],
sheathotomy [14,15], or grid argon laser photocoag-
ulation [16]. Anticoagulant therapy in the management
of BRVO only produced limited effects and many
complications during systemic administration. The
therapeutic effect of sheathotomy for BRVO is still
controversial and under investigation. Currently, the
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We designed a case series study to evaluate the outcome of intravitreal triamcinolone acetonide
for the treatment of macular edema due to branch retinal vein occlusion (BRVO). The prospective
comparative nonrandomized clinical interventional study included 27 patients (27 eyes) with
macular edema due to BRVO. The study group consisted of 16 patients who had accepted 
an intravitreal injection (IVI) of 4 mg triamcinolone acetonide. The control group included 
11 patients without IVI of triamcinolone acetonide. The mean follow-up was 103.00 36.24 days
in the study group and 94.55 36.31 days in the control group. In the study group, visual acuity
measurements improved significantly (p 0.001) from 0.77 0.43 logarithm of minimal angle of
resolution (logMAR) preoperatively to a best postoperative visual acuity of 0.44 0.43 logMAR.
Fourteen eyes (87.5%) gained improvement in visual acuity, with 10 eyes (62.5%) showing an
increase in visual acuity of at least two Snellen lines. All 16 patients showed significant macular
edema resolution in optical coherence tomography examination (p 0.001) and perivascular
leakage decrease in fluorescein angiography post-IVI. In the control group, baseline best-cor-
rected visual acuity and best-corrected visual acuity during the follow-up did not vary signifi-
cantly (p 0.294). In conclusion, IVI of triamcinolone acetonide can lead to an increase in visual
acuity and a resolution of macular edema in patients with BRVO.
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only proven therapy for macular edema due to BRVO
is macular grid argon laser photocoagulation, but 
the clinical outcomes are often disappointing (aver-
age improvement in vision of 1.33 Snellen lines) [16].
A recent addition to the options for treatment of macu-
lar edema due to BRVO has been intraocular injection
of corticosteroids. We tried intravitreal triamcinolone
acetonide to treat BRVO with associated macular
edema and evaluated its effect.
MATERIALS AND METHODS
Patient selection
The comparative nonrandomized clinical interven-
tional study included 27 patients (27 eyes) with 
macular edema due to BRVO (only one quadrant
involvement). There were 16 patients (13 men and 3
women; 16 eyes; 8 right eyes) in the study group and
11 patients (4 men and 7 women; 11 eyes; 7 right
eyes) in control group. No cataract surgery was per-
formed either before, in combination with, or after,
intravitreal injection (IVI). Those patients enrolled in
the study group agreed to accept an IVI of 4 mg tri-
amcinolone acetonide. Patients who refused IVI of
triamcinolone acetonide were assigned to the control
group. In three eyes (27%) in the control group (cases
1, 3 and 10), retinal argon laser photocoagulation was
performed for treating BRVO during follow-up,
whereas others accepted only regular follow-up visit.
The mean age of the study group was 55.75 10.00
years and the mean age of the control group was
54.91 9.26 years. The mean follow-up duration was
103.00 36.24 days (range, 54–186 days) in the study
group and 94.55 36.31 days (range, 60–154 days) in
the control group (Table 1).
We performed a series of ophthalmic examina-
tions at study baseline and at repeated intervals
afterwards as visual acuity [best-corrected visual
acuity was determined from Snellen chart and calcu-
lated as the logarithm of minimal angle of resolution
(logMAR)], slit-lamp biomicroscopy, pneumotono-
metry (Full auto Tonometer TX-F; Canon, New York,
USA), ophthalmoscopy and optical coherence tomo-
graphy (Stratus OCTTM III Model 3000; Zeiss
Humphrey, New York, USA). For the study group,
we performed the above examinations during the 1st
week postinjection, twice at 2-weekly intervals, and
then at routine monthly intervals. For the control
group, the same examinations were performed once
a month. The main outcome measures were best-
corrected visual acuity, macular thickness assessed
with optical coherence tomography (OCT), and post-
operative complications.
Surgical procedure
IVI of triamcinolone acetonide was performed under
sterile conditions in the operation theater with an
operation microscope. Povidone-iodine (Saint-iodine®;
Patron, Gangshan, Taiwan) was applied before IVI.
Then, the patient was completely draped. We used a 
lid speculum to open the eye. Paracentesis into the
anterior chamber was performed and some aqueous
fluid was aspirated by using a 26-gauge needle with a
1.0-mL tuberculin syringe to decrease the volume of
the eye. The injection of 4 mg (0.1 mL) crystalline tri-
amcinolone acetonide (KenacortTM-A; Bristol-Myers
Squibb, Taipei, Taiwan) into the vitreous cavity was
performed using a sharp 27-gauge needle through the
pars plana, 4 mm from the limbus. After that, an anti-
biotic eyedrop (Tobramycin–Tobrex®; Alcon, Belgium)
was applied.
Statistical analysis
Statistical calculations were performed using standard
software (MS Excel 2003; Microsoft Co., Redmond,
WA, USA). Data were compared using paired t-test.
A p value 0.05 was considered to be significant.
RESULTS
In the study group, visual acuity measurements
improved significantly (p 0.001) from 0.77 0.43
logMAR preoperatively to a best postoperative visual
acuity of 0.44 0.43 logMAR. Fourteen eyes (87.5%)
showed visual acuity improvement and two eyes
Table 1. Baseline clinical characteristics
Study group Control group
Number 16 patients 11 patients 
(16 eyes; (11 eyes;
8 right eyes) 7 right eyes)
Male : Female 13 : 3 4 : 7
Mean age (yr) 55.75 10.00 54.91 9.26
Mean follow-up (d) 103.00 36.24 94.55 36.31
(12.5%) remained the same during follow-up com-
pared with study baseline. Measured in Snellen lines,
10 eyes (62.5%) showed an improvement by at least 2
Snellen lines or more (Table 2). In the control group,
after argon laser photocoagulation or just continuous
observation, only three eyes (27.27%) showed visual
acuity improvement. Four eyes (36.36%) had the same
visual acuity during follow-up compared with base-
line. For four eyes (36.36%), visual acuity measure-
ments after the baseline measurement were worse than
those at the start of the study (Table 3). In the study
group, the visual acuity was significantly increased
postoperatively (p 0.001). On the other hand, the
visual acuity of the control group did not vary signi-
ficantly (p 0.294) between baseline best-corrected
visual acuity and best-corrected visual acuity during
follow-up.
In all the cases in the study group, the decline of
cotton wool spots, retinal hemorrhage, and macular
edema were noted during fundus examination after
IVI of triamcinolone acetonide (Figure 1), and floures-
cein angiography showed vascular leakage decrease
postoperatively (Figure 2).
OCT examination of the study group demonstrated
clinical improvement in macular edema (p 0.001)
postoperatively (Figure 3). Preinjection foveal thickness
ranged from 253 to 782 m (mean, 525 173.34 m).
Final foveal thickness ranged from 170 to 421 m
(mean, 261.50  79.02 m) with an average decrease
of 46.90% in foveal thickness (Table 2). In the control
group, the foveal thickness measured by OCT between
baseline and final measurements did not show signif-
icant resolution (p 0.170). Baseline foveal thickness
ranged from 215 to 717 m (mean, 428.27 167.65 m).
Final foveal thickness ranged from 192 to 725 m
(mean, 396.91 175.28 m) with an average decrease
of 6.48% in foveal thickness (Table 3).
Recurrence of macular edema and a decrease in
visual acuity occurred in one case of the study group 
3 months postoperatively. Subsequently, the patient
accepted a second injection of triamcinolone ace-
tonide. After that, the macular edema subsided and
visual acuity improved again.
In the study group, no obvious complication was
noted postoperatively, but three patients (18.75%) had
ocular hypertension (intraocular pressure 22 mmHg)
which could be controlled to a normal range by
antiglaucomatous medication. No pre-existing cata-
racts progressed and no cataract formation was noted
in the study group during follow-up and no eye
required cataract surgery. No serious side effects, such
as postoperative endophthalmitis or retinal detach-
ment, occurred.
DISCUSSION
Intravitreal triamcinolone acetonide was first used
by Antcliff et al to treat uveitic cystoid macular edema
[17]; consequently, many researchers tried intravitreal
triamcinolone acetonide to treat macular edema
caused by different diseases such as diabetic macular
edema [18,19] and proliferative diabetic retinopathy
[20]. Intravitreal triamcinolone acetonide has also
been used to treat retinal vasculitis caused by retinal
vascular diseases such as Vogt-Koyanagi-Harada syn-
drome [21], sympathetic ophthalmia [22], central reti-
nal vein occlusion [23] and diabetic papillopathy [24],
but studies mentioning BRVO are still rare.
Jonas et al injected 20–25 mg triamcinolone ace-
tonide into 10 eyes of 10 patients with BRVO in the
study group while 18 patients with BRVO in the con-
trol group did not receive IVI [25]. They found that
visual acuity increased significantly in the study vs.
control group during the follow-up period. There were
no significant complications except that seven eyes
(70%) in the study group had elevation of intraocular
pressure (21 mmHg) which was readily normalized
by topical antiglaucomatous medication.
Lee and Shah examined the effect of triamcinolone
acetonide IVI in six patients with cystoid macular
edema secondary to BRVO [26]. Three of six eyes
showed improvement in vision. All three patients
without vision improvement accepted a second injec-
tion. All six eyes had an increase in visual acuity at the
final follow-up visit. Five (83.3%) of six eyes showed
an improvement of at least two lines of vision. OCT 
of five eyes (one patient was seen at a satellite office
without OCT capabilities) showed a decrease of cys-
toid macular edema in four eyes (80%). One patient
had a postoperative rise in intraocular pressure,
requiring a trabeculectomy. In a retrospective study
of 13 eyes of 13 patients (mean age, 68 years) who
underwent IVI with 4 mg triamcinolone acetonide for
macular edema due to BRVO, Cekic et al observed a
significant decrease in retinal thickness in all cases
with OCT, accompanied by a gain in final visual acuity
in half the patients [27].
IVI of triamcinolone acetonide for BRVO
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From the results of the present study, we found that
intravitreal triamcinolone acetonide may be effective
in the treatment of macular edema and increase visual
acuity in patients with branch retinal vein occlusion. It
also appears effective in decreasing vascular leakage.
All 16 patients in the study group showed a decrease
in central foveal thickness in OCT examination. The
patients in the study group experienced a significant
increase in visual acuity (p 0.001), while those in the
control group did not (p 0.294).
The anti-inflammatory reaction hypotheses of corti-
costeroid are as follows. First, it may reduce capillary
permeability by increasing the activity and density of
the tight junctions in the retinal capillary endothelium
[28]. Second, it may inhibit the metabolic pathway of
vascular endothelial growth factor, a major vascular
permeability-increasing factor [29,30]. Third, it may
also attenuate leukostasis and blood–retinal barrier
breakdown [31]. Our hypothesis for why intravitreal
triamcinolone acetonide is more effective for early
BRVO is as follows.
Intraretinal intercellular structures are disrupted
due to chronic macular edema. Although numerous
retinal cells are damaged due to capillary non-
perfusion, partial retinal cell function and structure
may be reversible if early resolution of macular
edema can be reached by treating with intravitreal
triamcinolone acetonide.
One patient in the study group suffered from
recurrence of macular edema and a decrease in visual
A
B
Figure 1. Case 5 in study group: (A) Preinjection color fundus
photograph of the right eye (53-year-old male) with inferiotempo-
ral branch vein occlusion demonstrating the segmental pattern 
of intraretinal hemorrhage with multiple cotton-wool spots. The
veins of the involved area are dilated and tortuous. (B) After 1
week of intravitreal triamcinolone injection, intraretinal hemor-
rhage with cotton-wool spots has subsided.
Figure 2. Case 5 in study group: (A) Preinjection late-phase flu-
orescein angiography of the right eye shows a branch retinal vein
occlusion (temporal lower quadrant) with macular edema. It also
demonstrated severe fluorescein leakage and blockage secondary
to retinal hemorrhage. (B) Resolution of macular edema with
restoration of normal foveal contour were noted 1 week after intra-
vitreal triamcinolone injection. Fluorescein leakage also decreased.
A
B
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acuity 3 months postoperatively. Reinjection of tri-
amcinolone acetonide led to a visual acuity improve-
ment and a reduction in macular thickness. This
observation is similar to the study reported by Salinas-
Alaman et al, whose patient received a second injection
after 3 months [32].
In our case series, no toxic effects of triamcinolone
acetonide on the retina and optic nerve were noted in
the study group. Previous clinical and experimental
studies also demonstrated the safety of using intra-
ocular steroid [33–37].
The most common side effect reported after IVI 
of triamcinolone acetonide is a rise in intraocular
pressure. In our study, ocular hypertension (intra-
ocular pressure 22 mmHg) occurred in three eyes
(18.75%). This problem could be controlled by topical
antiglaucomatous treatment. Other studies also re-
vealed similar observations [38–41].
An increase in cataract formation has been des-
cribed in patients after IVI of triamcinolone acetonide.
Progression of cataract was observed in six of 26 eyes
in a study by Challa et al [42] and in four of seven eyes
in a study by Danis et al [43]. Jonas et al observed a pro-
gression in cataract in one of their patients, although
it was not a significant change [44]. Park et al found 
a progression in one of 10 eyes [45], and Martidis et al
noted a similar finding in one of eight eyes [46]. How-
ever, in our study, we did not observe any cataract
formation or deterioration in pre-existing cataracts in
the study group.
Intraocular infection is one of the most severe com-
plications after triamcinolone acetonide IVI. Moshfeghi
et al [47] and Nelson et al [48] observed infectious
endophthalmitis in their cases after intravitreal tri-
amcinolone acetonide injection. Non-infectious endo-
phthalmitis has also been reported by Nelson et al [48],
Moshfeghi et al [49], Roth et al [50], Chiu et al [51] and
Sutter and Gillies [52]. In none of the eyes in our study
group were postoperative infectious or non-infectious
endophthalmitis observed.
Figure 3. Case 12 in study group: (A) Preinjection cross-sectional optical coherence tomography shows cystoid macular edema in the
right eye. The retinal thickness map demonstrates marked retinal thickening. The mean central (1 mm diameter) thickness is 656mm
(normal mean central thickness is 210mm). (B) One month postinjection, optical coherence tomography demonstrates decline of the
cystoid macular edema. The mean central thickness is 259mm.
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The advantages of intravitreal triamcinolone aceto-
nide include avoiding systemic adverse effects, having
simultaneously high concentrations of drug at the site
of action, and no toxic effect on intraocular tissue.
The major limitations of our study are non-
randomized selection between study and control
groups, small number of patients in both study and
control groups, and the relatively short follow-up
period. Further study with longer follow-up and a
larger series is warranted to assess the long-term effi-
cacy and safety of intravitreal triamcinolone acetonide.
CONCLUSION
The application of triamcinolone acetonide IVI
showed a significant increase in visual acuity with a
decrease in macular edema and vascular leakage in
patients with BRVO. A side effect observed in our
study was an elevation of intraocular pressure, which
can be readily resolved by topical antiglaucomatous
medication. The results of this study suggest that
intravitreal triamcinolone acetonide may be an alter-
native therapeutic option for patients with macular
edema due to BRVO.
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